Sunvozertinib

A targeted therapy for non-small cell lung cancer

Sunvozertinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Sunvozertinib is an investigational tyrosine kinase inhibitor (TKI) designed for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It targets mutations in the epidermal growth factor receptor (EGFR), particularly those that confer resistance to first-generation EGFR inhibitors.

Mechanism of Action

Sunvozertinib functions by selectively inhibiting the activity of mutant forms of the EGFR, which are often implicated in the pathogenesis of NSCLC. By binding to the ATP-binding site of the EGFR, Sunvozertinib prevents the receptor's autophosphorylation and subsequent activation of downstream signaling pathways that promote cell proliferation and survival.

Clinical Development

Sunvozertinib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with NSCLC harboring EGFR mutations. These trials aim to determine the optimal dosing regimen and to assess the drug's ability to overcome resistance to other EGFR inhibitors.

Pharmacokinetics

The pharmacokinetic profile of Sunvozertinib includes its absorption, distribution, metabolism, and excretion characteristics. It is designed to have a favorable oral bioavailability, allowing for convenient administration. The drug is metabolized primarily in the liver and excreted via the renal and biliary systems.

Adverse Effects

As with other TKIs, Sunvozertinib may cause a range of adverse effects. Common side effects include skin rash, diarrhea, and fatigue. More serious adverse effects can include interstitial lung disease and hepatotoxicity, which require careful monitoring during treatment.

Research and Future Directions

Ongoing research is focused on understanding the full spectrum of mutations that Sunvozertinib can target and on developing combination therapies to enhance its efficacy. Studies are also exploring its use in earlier lines of therapy and in combination with other targeted agents or immunotherapy.

Related Pages

• Non-small cell lung cancer
• Tyrosine kinase inhibitor
• Epidermal growth factor receptor
• Cancer treatment